Fezolinetant is designed to reduce the frequency and severity of VMS associated with menopause by inhibiting neurokinin B binding on the kisspeptin/neurokinin/dynorphin neuron.
Sexual dysfunction during perimenopause among women prescribed hormone replacement therapy may have more to do with psychosocial factors, not menopausal symptoms.
The objective of this study was to investigate the associations between endogenous FSH levels and BMD, BMA, and body composition in older adults, independent of estradiol and testosterone levels.
Scientific statement by AHA detailing the current understanding of menopause transition and its impact on the risk for postmenopausal cardiovascular disease.
Among women with menopausal vasomotor symptoms, severity rather than frequency of hot flushes and night sweats is associated with an increased risk for CVD.
In recently menopausal women using hormone treatment, circulating levels of pituitary-ovarian hormones are associated with changes in white matter hyperintensities.
